ArticleJournal of the American Chemical Society2026
Discriminating Post-Transplant Rejection from Infection by Detecting TCR-CD3 Oligomerization on Extracellular Vesicles Using a Ratiometric Caliper Probe.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-transplant rejection and infection remain significant obstacles to long-term patient survival. However, there is currently no standardized assay to simultaneously assess an individual patient's risk for both complications. Here, we demonstrate that T cell receptor (TCR)-CD3 oligomers on extracellular vesicles (EVs) represent a promising biomarker for acute cellular rejection. To leverage this, we developed a caliper-shaped aptamer probe to quantify the ratio of TCR-CD3 oligomeric to monomeric EVs derived from CD8+ cytotoxic T cells. This method inherently normalizes the differences in overall EV abundance and minimizes variability arising from plasma input volume (5-15 μL) and storage conditions, thereby ensuring highly robust results. In murine models, the assay yielded markedly higher fluorescence ratios in mice experiencing allograft rejection than in those with infection (mean 0.26 vs 0.14). Crucially, in a clinical cohort of 34 transplant recipients, the assay reliably distinguished rejection and infection with overlapping clinical manifestation and also accurately identified rejection even in patients with concurrent rejection and infection. At a diagnostic cutoff value of 0.69, the assay demonstrated robust performance, with an area under the curve of 0.85, corresponding to a sensitivity of 71% and a specificity of 90%. Ultimately, this approach offers a minimally invasive tool for routine immune monitoring, with the potential to guide immunosuppressive therapy and reduce the reliance on biopsies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.